Metaplastic breast carcinoma (MBC) is a rare histological breast cancer subtype characterized by mesenchymal elements and poor clinical outcome. A large fraction of MBCs harbor defects in breast cancer 1 (BRCA1). As BRCA1 deficiency sensitizes tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (PARP) inhibitors, we sought to investigate the response of BRCA1-deficient MBCs to the PARP inhibitor olaparib. To this end, we established a genetically engineered mouse model (GEMM) for BRCA1-deficient MBC by introducing the MET proto-oncogene into a BRCA1-associated breast cancer model, using our novel female GEMM ES cell (ESC) pipeline. In contrast to carcinomas, BRCA1-deficient mouse carcinosarcomas resembling MBC show intrinsic resistance to olaparib caused by increased P-glycoprotein (Pgp) drug efflux transporter expression. Indeed, resistance could be circumvented by using another PARP inhibitor, AZD2461, which is a poor Pgp substrate. These preclinical findings suggest that patients with BRCA1-associated MBC may show poor response to olaparib and illustrate the value of GEMM-ESC models of human cancer for evaluation of novel therapeutics. resistance | mouse model | breast cancer | BRCA1 | PARP P oly(ADP-ribose) polymerase (PARP) inhibition provides a promising therapeutic strategy for targeting homologous recombination (HR)-deficient tumors, such as breast cancer 1 (BRCA1)-mutated cancers (1). Indeed, clinical phase I and phase II trials have shown potent anticancer activity of small molecule inhibitors of PARP, such as olaparib, in patients with BRCA1-associated breast cancer (2, 3). However, it remains to be established whether different breast cancer subtypes in BRCA1 mutation carriers respond equally to PARP inhibition. Reduced sensitivity of breast cancers to anticancer drugs has frequently been associated with an epithelial-to-mesenchymal transition (EMT) (4-7). Metaplastic breast carcinomas (MBCs) are a subset of triple-negative breast cancers (TNBCs) characterized by a claudin-low and EMT-like phenotype (8) and a poor prognosis compared with other TNBCs (9). More than 60% of MBCs have BRCA1 promoter methylation, raising the question whether these tumors can be effectively targeted by using PARP inhibitors (10). To address this issue in an experimentally controlled setting, we set out to generate a genetically engineered mouse model (GEMM) of BRCA1-deficient MBC by inducing EMT via MET overexpression in a previously established GEMM of BRCA1-mutated breast cancer. We report that EMT is associated with olaparib resistance and can be effectively bypassed by administration of AZD2461, a PARP inhibitor with low affinity for the P-glycoprotein (Pgp) drug efflux transporter.
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Results

Development of a GEMM-ESC Strategy for Mouse Mammary Tumor
Models. GEMMs have the potential to capture the cell-intrinsic and cell-extrinsic factors that drive de novo tumor formation, making them exceptionally valuable for cancer research (11) . To speed up the development of novel multiallele GEMMs of human cancer, we previously developed a GEMM-ES cell (ESC) strategy, which permits rapid introduction of mutant alleles into ESCs derived from existing, well-characterized GEMMs and subsequent production of experimental cohorts of chimeric mice that can be directly used for preclinical studies (12, 13) . To validate candidate oncogenes and their contribution to therapy resistance in BRCA1-associated breast cancer, we set out to develop a female GEMM-ESC pipeline, based on our K14cre; Brca1 F/F ;Trp53 F/F (KB1P) mouse mammary tumor model, in which Cre-mediated stochastic inactivation of BRCA1 and p53 leads to mammary tumors and, to a lesser extent, skin tumors (14) . We derived clonal ESC lines from male and female KB1P blastocysts and validated their quality and potency by producing chimeric mice via blastocyst injection (Fig. 1A) . As expected, sex conversion was evident for the male KB1P clone C3. Clone C3 and female clone A2 contributed well to chimeras, with the majority of animals scoring greater than 40% chimerism, and displayed germ-line transmission. For a second female KB1P clone (C7), more than half of the chimeras showed low chimerism and did not display germ-line transmission, indicating that the quality of this clone was suboptimal (Fig. 1B) .
Female ESCs tend to undergo XO conversion during in vitro culture. Indeed, copy number variation (CNV) sequencing of female KB1P ESC lines showed loss of one X-chromosome, which was confirmed by whole chromosome painting ( Fig. S1 A and B) .
Significance
Poly(ADP-ribose) polymerase (PARP) inhibitors hold promise for patients with breast cancer 1 (BRCA1)-associatated cancers but are anticipated to give rise to resistance. We show that mouse mammary tumors resembling BRCA1-associated metaplastic breast carcinoma display intrinsic resistance to the PARP inhibitor olaparib as a result of increased P-glycoprotein drug efflux transporter expression. These findings may have implications for ongoing clinical trials.
Previous studies reported that XO mice are viable and fertile but can exhibit some degree of growth retardation, high-frequency hearing loss, reduced thyroid activity, reduced body temperature, and behavioral abnormalities (15, 16) . Chimeric mice derived from female KB1P ESCs did not display any abnormalities, were fertile, and gave germ-line transmission, indicating that our female KB1P ESCs contribute to the development of healthy chimeric offspring regardless of their XO status.
Mammary Tumor Development in KB1P Chimeric Mice. Next, we monitored female KB1P chimeras for development of mammary tumors and compared the mammary tumor latency to that of the original KB1P GEMM (Fig. 1C) . Chimeras of KB1P clone A2 developed tumors with a significantly increased median latency of 266 d vs. 209 d for the original KB1P GEMM (P < 0.0001), most likely because of the smaller number of mammary and skin epithelial cells that undergo Cre-mediated loss of BRCA1 and p53 compared with the original model (Fig. 1C) . There was no significant difference in tumor latency for chimeras of KB1P clone C7, with a median tumor latency time (t 50 ) of 237 d.
Histologically, mammary tumors from KB1P chimeras were estrogen and progesterone receptor-negative and were classified as solid carcinomas, thus showing morphological features comparable to KB1P GEMM tumors ( Fig. 1 D and E) . To assess inactivation of BRCA1 and p53 in tumors from KB1P chimeras, we performed Southern blot analysis, which confirmed recombination of the conditional Brca1F and Trp53F alleles in all cases (Fig. S2 ). Given that BRCA1 loss leads to genomic instability, we assessed DNA CNVs in mammary tumors from KB1P chimeras by CNV sequencing, which confirmed that KB1P chimeric tumors display genomic instability to the same extent as KB1P GEMM tumors (Fig. 1F) . Thus, our female GEMM-ESC approach yields healthy chimeras that develop mammary tumors that closely resemble tumors from the original mouse model, and is therefore a novel tool to study breast cancer.
MET Accelerates Mammary Tumor Development in KB1P Chimeric
Mice. We next determined if the female GEMM-ESC strategy would be suitable to study the contribution of candidate oncogenes to mammary tumor formation. To allow rapid introduction of additional modifications, we made use of the Flp/FRT recombinase-mediated cassette exchange strategy (13, 17) (Fig. 2A) . Female KB1P ESC clone A2 was targeted with an FRT homing cassette into the 3′UTR of the Col1a1 locus to produce K14cre; Brca1 F/F ;Trp53 F/F ;Col1a1 FRT (KB1P-Col1a1) ESCs (Fig. S3A ). Next, a Cre-inducible allele of the MET receptor tyrosine kinase, which is associated with EMT and therapy resistance (18, 19) , and expressed at high levels in breast cancer (20) (21) (22) , was introduced in KB1P-Col1a1 ESC clone A2.1 to produce K14cre;Brca1
inv-CAG-Met-Luc (KB1P-MET) ESCs (Fig. S3B) . To allow for in vivo monitoring of MET expression by bioluminescence imaging, the Met cDNA was fused to a codon-optimized firefly luciferase (Luc) gene via an internal ribosomal entry site (Fig. S3C ). Successful targeting of the FRT homing cassette and subsequent shuttling of the Cre-inducible invCAG-Met-Luc construct was confirmed by Southern blot analysis (Fig. S3 D and E) . Luciferase expression was confirmed by bioluminescence imaging of AdenoCre-treated KB1P-MET ESCs (Fig. S3F ). KB1P-Col1a1 and KB1P-MET ESCs produced high-grade female chimeras, which were monitored for mammary tumor development ( Fig. 2B and Fig.  S4A ). Whereas KB1P and KB1P-Col1a1 chimeras developed mammary tumors with comparable latency, KB1P-MET chimeras developed mammary tumors with a significantly reduced latency of 176 d (P < 0.001; Fig. 2C ), demonstrating that MET overexpression accelerates BRCA1-associated tumor development.
KB1P-MET Chimeras Develop Mammary Tumors with Metaplastic
Characteristics. Histopathological analysis revealed that all mammary tumors from KB1P-Col1a1 chimeras were classified as carcinomas. In contrast, more than half of KB1P-MET chimeras developed carcinosarcomas, based on the presence of spindle cells that show E-cadherin loss and vimentin expression, indicating that MET expression promotes the development of metaplastic tumors with an EMT-like phenotype (Fig. 2 D and E) . KB1P-MET carcinosarcomas also showed a claudin-low gene expression pattern, which is a key characteristic of breast cancers with an EMT phenotype ( Fig. 2F) (8) . In contrast to KB1P-MET carcinomas, mice bearing KB1P-MET carcinosarcomas developed tumors with a shorter latency ( Table S1 ), indicating that these metaplastic tumors are more aggressive than carcinomas. Southern blot analysis confirmed Cre-mediated recombination of Brca1 and Trp53 in all tumors (Fig. S4B) .
To confirm that KB1P-MET carcinosarcomas had undergone an EMT, we performed RNA-sequencing and determined the expression level of a panel of EMT signature genes (Fig. S5 ). KB1P and KB1P-MET tumors clustered perfectly into three groups. KB1P tumors express high levels of epithelial genes; KB1P-MET carcinomas express high levels of epithelial and mesenchymal genes, whereas KB1P-MET carcinosarcomas express high levels of mesenchymal genes. These results show that KB1P-MET mouse carcinosarcomas display an EMT phenotype and, in this respect, resemble BRCA1-deficient MBC in humans (23).
KB1P-MET Carcinosarcomas Display Resistance to the PARP Inhibitor
Olaparib. Mammary tumors from GEMMs can be transplanted orthotopically into WT syngeneic female mice while retaining their morphological features, molecular characteristics, and drugsensitivity profile (24) . To confirm that mammary tumors from chimeric mice can be used for transplantation and intervention studies, we orthotopically transplanted 1-mm 3 tumor fragments In line with previous studies (24, 26) , KB1P-Col1a1 carcinomas regressed upon cisplatin and olaparib treatment (Fig. 3) . Likewise, KB1P-MET tumors shrank upon cisplatin treatment, regardless of their morphological status (Fig. 3A) . In contrast, whereas KB1P-MET carcinomas regressed upon olaparib treatment, KB1P-MET carcinosarcomas were intrinsically resistant to olaparib (Fig. 3B) . This suggests that olaparib resistance is not induced by MET expression per se, but rather by MET-associated EMT.
Increased Pgp Expression in KB1P-MET Carcinosarcomas Causes
Resistance to Olaparib. Next, we determined if KB1P-MET carcinosarcomas display increased expression of drug efflux transporters, which were previously implicated in olaparib resistance (26) . Indeed, we detected increased mRNA expression of the Abcb1a and Abcb1b genes, both encoding Pgp, in KB1P-MET carcinosarcomas, indicating that these tumors may display resistance by increased efflux of olaparib (Fig. 4A) . Moreover, Abcb1a and Abcb1b mRNA levels were strongly correlated to the EMT status of the KB1P-MET tumors (Fig. 4B) .
To demonstrate that Pgp mediates olaparib resistance of KB1P-MET carcinosarcomas,, we determined the response of KB1P-MET carcinosarcomas to olaparib combined with the Pgp inhibitor tariquidar (XR9576) (27) . A KB1P-MET carcinosarcoma with high Pgp expression (donor 2) responded well to the combination therapy, confirming that olaparib resistance is mediated by increased drug efflux by Pgp in this tumor (Fig. 4C) . Olaparib resistance of a KB1P-MET carcinosarcoma with low Pgp expression (donor 3) could not be bypassed by coadministration of tariquidar, indicating that resistance of this carcinosarcoma was driven by a different mechanism.
Next, we determined the response of KB1P-MET carcinosarcomas to AZD2461, a PARP inhibitor with strongly reduced affinity to Pgp (28) . KB1P-MET carcinosarcomas with high Pgp expression (donors 1 and 2) responded well to AZD2461, confirming Pgp-mediated resistance to olaparib (Fig. 4D) .
To assess whether also human TNBCs with EMT features have elevated Pgp levels, we evaluated ABCB1 gene expression in several human TNBC subtypes. Similar to mouse KB1P-MET carcinosarcomas and in contrast to basal-like TNBCs with epithelial morphology, the majority of MBCs have a claudin-low phenotype (29, 30) . We therefore determined ABCB1 mRNA levels in claudin-low TNBCs and compared them vs. basal-like TNBCs. As expected, claudin-low TNBCs showed a significantly higher EMT score than basal-like TNBCs (Fig. 5A ). In addition, claudin-low TNBCs showed significantly increased ABCB1 mRNA levels compared with basal-like TNBCs (Fig. 5B) , suggesting that also human MBCs may show intrinsic resistance to olaparib as a result of elevated Pgp-mediated drug extrusion.
Discussion
In this study, we describe a novel female GEMM-ESC strategy for rapid introduction of additional mutant alleles into existing complex GEMMs of human breast cancer. We also demonstrate the utility of this approach to study cause-and-effect relations in BRCA1-associated breast cancer. An advantage of the female GEMM-ESC approach is that, when female chimeras have been generated, these mice can directly be used for tumor monitoring without further breeding. This strategy effectively reduces time and costs spent on breeding, and-equally importantly-it reduces the total number of mice used to generate a new mouse line. Mammary tumors that develop in chimeric mice derived from GEMM-ESCs are transplantable and therefore suitable for a wide range of preclinical in vivo studies. Moreover, the GEMM-ESC strategy is compatible with CRISPR/Cas9 technology, thus creating a powerful tool for fast-track generation of tailored in vivo models to propel basic and translational cancer research in the era of personalized medicine.
We used the female GEMM-ESC strategy to establish a novel mouse model for BRCA1-mutated metaplastic breast cancer by forcing MET expression in our previously established KB1P mouse mammary tumor model. We showed that the resulting KB1P-MET carcinosarcomas are unresponsive to olaparib treatment. Given that EMT is associated with more aggressive breast cancer subtypes (5), it is perhaps not surprising that breast cancer subtypes with mesenchymal elements respond poorly to therapeutics. Notably, several KB1P-MET carcinosarcomas showed elevated levels of the drug efflux transporter Pgp, an observation that was previously reported in olaparib-resistant KB1P tumors (26) , but was never linked to their morphological status. In addition, we found elevated ABCB1 expression in human EMT-like TNBCs with a claudin-low gene expression pattern, suggesting that human BRCA1-deficient MBCs also may display reduced sensitivity to olaparib as a result of Pgpmediated drug efflux. Interestingly, increased Pgp expression was also associated with olaparib resistance in BRCA2-deficient carcinosarcomas from K14cre;Brca2 unresponsiveness to PARP inhibition could not be explained by drug efflux. This particular tumor (donor 3) showed decreased expression of 53BP1 (Fig. S6A) , which was previously reported to restore HR and thereby cause olaparib resistance in BRCA1-deficient tumors (24, 25) . Indeed, RAD51 foci formation was detected in this tumor following irradiation, suggesting that restoration of HR as a result of 53BP1 loss is the most plausible cause of resistance to olaparib and AZD2461 ( Fig. S6 B and C) .
We have previously shown that restoration of HR by somatic mutation of Trp53bp1 encoding 53BP1 occurs in 25% of KB1P mammary tumors with acquired resistance to AZD2461 (28) . Whether reduced 53BP1 expression in the AZD2461-resistant KB1P-MET carcinosarcoma is a consequence of MET-induced EMT or caused by (epi)genetic alterations of Trp53bp1 remains to be determined. Although clinical phase I and phase II trials have demonstrated anticancer activity of olaparib in patients with BRCA1-associated breast cancer (2, 3) , the response of BRCA1-associated MBCs has yet to be established. Our data show that mouse mammary tumors resembling BRCA1-associated MBC display intrinsic resistance to olaparib as a result of increased Pgp drug efflux transporter expression. These preclinical findings may have implications for ongoing clinical trials.
Methods
All animal work was performed in accordance with protocol A11002 approved by the Animal Ethics Committee of The Netherlands Cancer Institute (Amsterdam). Detailed protocols regarding CNV sequencing, whole chromosome painting, Southern blot analysis, targeting ESCs, AdCre infection, bioluminescence imaging, RNA sequencing, EMT signature and human data sets, RAD51 foci analysis, transplantations, histology, and RT-MLPA are described in SI Methods.
Antibodies. All antibodies and their dilutions are summarized in Table S2 .
Generation of Chimeric Mice. ESCs were derived from KB1P mice and cultured as described previously (13) . Male and female ESCs were injected into C57BL/6N blastocysts and implanted into pseudopregnant B6CBAF1/Ola foster mice. The percentage of chimerism of the resulting chimeras was scored by the absence of host-derived coat color. Germ-line transmission was determined by crossing chimeric mice to KB1P (FVB) mice, and the offspring were scored for coat color transmission.
Targeting Col1a1 Locus and Flip-in of Met. Female KB1P ESCs were targeted with the Col1a1-frt targeting plasmid followed by Flp-mediated integration of the frt-invCAG-Met-Luc vector as described previously (13, 17) . Further details are described in SI Methods.
